+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Type 1 Diabetes Drugs Market 2021-2025- Product Image
Global Type 1 Diabetes Drugs Market 2021-2025- Product Image

Global Type 1 Diabetes Drugs Market 2021-2025

  • ID: 5359081
  • Report
  • May 2021
  • Region: Global
  • 120 pages
  • TechNavio

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher has been monitoring the type 1 diabetes drugs market and it is poised to grow by $2.83 billion during 2021-2025, progressing at a CAGR of almost 6% during the forecast period. The report on the type 1 diabetes drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of type 1 diabetes and feasibility of early diagnosis of type 1 diabetes.

The type 1 diabetes drugs market analysis includes the product segment and geographic landscape.

The type 1 diabetes drugs market is segmented as below:

By Product
  • Long-acting insulins
  • Rapid-acting insulins
  • Pre-mixed insulins
  • Non-insulin drugs
By Geography
  • North America
  • Europe
  • Asia
  • ROW
This study identifies the expected launch of novel products as one of the prime reasons driving the type 1 diabetes drugs market growth during the next few years.

The report on type 1 diabetes drugs market covers the following areas:
  • Type 1 diabetes drugs market sizing
  • Type 1 diabetes drugs market forecast
  • Type 1 diabetes drugs market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading type 1 diabetes drugs market vendors that include Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Co., MannKind Corp., Novo Nordisk AS, Actiza Pharmaceutical Pvt. Ltd., Sanofi SA, and Viatris Inc. Also, the type 1 diabetes drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • MORE
Executive Summary
  • Market Overview
Market Landscape
  • Market ecosystem
  • Market characteristics
  • Value chain analysis
Market Sizing
  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025
Five Forces Analysis
  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
Market Segmentation by Product
  • Market segments
  • Comparison by Product
  • Long-acting insulins - Market size and forecast 2020-2025
  • Rapid-acting insulins - Market size and forecast 2020-2025
  • Pre-mixed insulins - Market size and forecast 2020-2025
  • Non-insulin drugs - Market size and forecast 2020-2025
  • Market opportunity by Product
Customer Landscape

Geographic Landscape
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends
Vendor Landscape
  • Overview
  • Vendor landscape
  • Landscape disruption
Vendor Analysis
  • Vendors covered
  • Market positioning of vendors
  • Actiza Pharmaceutical Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • Novo Nordisk AS
  • Sanofi SA
  • Viatris Inc.
Appendix
  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations
List of Exhibits
  • Key Finding 1
  • Key Finding 2
  • Key Finding 3
  • Key Finding 5
  • Key Finding 6
  • Key Finding 7
  • Key Finding 8
  • Parent market
  • Market characteristics
  • Offerings of vendors included in the market definition
  • Market segments
  • Global - Market size and forecast 2020 - 2025 ($ million)
  • Global market: Year-over-year growth 2020 - 2025 (%)
  • Five forces analysis 2020 & 2025
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition - Five forces 2020
  • Long-acting insulins - Market size and forecast 2020-2025 ($ million)
  • Long-acting insulins - Year-over-year growth 2020-2025 (%)
  • Rapid-acting insulins - Market size and forecast 2020-2025 ($ million)
  • Rapid-acting insulins - Year-over-year growth 2020-2025 (%)
  • Pre-mixed insulins - Market size and forecast 2020-2025 ($ million)
  • Pre-mixed insulins - Year-over-year growth 2020-2025 (%)
  • Non-insulin drugs - Market size and forecast 2020-2025 ($ million)
  • Non-insulin drugs - Year-over-year growth 2020-2025 (%)
  • Customer landscape
  • Impact of drivers and challenges
  • Vendor landscape
  • Landscape disruption
  • Industry risks
  • Vendors covered
  • Market positioning of vendors
  • Actiza Pharmaceutical Pvt. Ltd. - Overview
  • Actiza Pharmaceutical Pvt. Ltd. - Product and service
  • Actiza Pharmaceutical Pvt. Ltd. - Key offerings
  • Actiza Pharmaceutical Pvt. Ltd. - Key customers
  • Actiza Pharmaceutical Pvt. Ltd. - Segment focus
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product and service
  • Astellas Pharma Inc. - Key offerings
  • Astellas Pharma Inc. - Key customers
  • Astellas Pharma Inc. - Segment focus
  • AstraZeneca Plc - Overview
  • AstraZeneca Plc - Product and service
  • AstraZeneca Plc - Key offerings
  • AstraZeneca Plc - Key customers
  • AstraZeneca Plc - Segment focus
  • Biocon Ltd. - Overview
  • Biocon Ltd. - Business segments
  • Biocon Ltd. - Key offerings
  • Biocon Ltd. - Key customers
  • Biocon Ltd. - Segment focus
  • Bristol-Myers Squibb Co. - Overview
  • Bristol-Myers Squibb Co. - Product and service
  • Bristol-Myers Squibb Co. - Key offerings
  • Bristol-Myers Squibb Co. - Key customers
  • Bristol-Myers Squibb Co. - Segment focus
  • Eli Lilly and Co. - Overview
  • Eli Lilly and Co. - Business segments
  • Eli Lilly and Co. - Key offerings
  • Eli Lilly and Co. - Key customers
  • Eli Lilly and Co. - Segment focus
  • MannKind Corp. - Overview
  • MannKind Corp. - Business segments
  • MannKind Corp. - Key offerings
  • MannKind Corp. - Key customers
  • MannKind Corp. - Segment focus
  • Novo Nordisk AS - Overview
  • Novo Nordisk AS - Business segments
  • Novo Nordisk AS - Key offerings
  • Novo Nordisk AS - Key customers
  • Novo Nordisk AS - Segment focus
  • Sanofi SA - Overview
  • Sanofi SA - Business segments
  • Sanofi SA - Key offerings
  • Sanofi SA - Key customers
  • Sanofi SA - Segment focus
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Key customers
  • Viatris Inc. - Segment focus
  • Currency conversion rates for US$
  • Research Methodology
  • Validation techniques employed for market sizing
  • Information sources
  • List of abbreviations
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • MORE
The publisher recognizes the following companies as the key players in the global type 1 diabetes drugs market: Astellas Pharma Inc., AstraZeneca Plc, Biocon Ltd., Bristol-Myers Squibb Co., Eli Lilly and Co., MannKind Corp., Novo Nordisk AS, Actiza Pharmaceutical Pvt. Ltd., Sanofi SA, and Viatris Inc.

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is the expected launch of novel products.'

According to the report, one of the major drivers for this market is the growing prevalence of type 1 diabetes.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Biocon Ltd.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • MannKind Corp.
  • Novo Nordisk AS
  • Actiza Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Viatris Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll